Growth Regulation of L-929 Mouse Fibroblasts by Steroid Hormones and Anti-Hormones in Serum Containing and Serum Free Media

  • I. Jung-Testas
  • E. E. Baulieu
Conference paper
Part of the Proceedings in Life Sciences book series (LIFE SCIENCES)


Mouse L-929 fibroblasts contain 3 distinct steroid hormone receptors, RG for glucocorticosteroids, RA for androgens and RE for estrogens. There is no progesterone receptor. Sedimentation coefficient of receptors in low salt medium is ∿ 7–8 S and affinity for their respective hormones is very high (KDeq ∿ 1 nM). RA binds androgens, anti-androgens (e.g. cyproteron acetate) and progesterone, and somewhat estradiol (but not DES, a synthetic estrogen). RE binds exclusively estrogens and anti-estrogens (e.g. tamoxifen), including DES. RA and RE do not bind glucocorticosteroids. RG binds glucocorticosteroids and progesterone, but neither androgens nor estrogens. At physiological concentrations, androgens or estrogens increase the rate of cell multiplication, and specific anti-hormones inhibit the related growth effect. In the presence of dexamethasone, cell multiplication is strongly decreased, and this effect can be abolished by addition of a new antiglucocorticosteroid, RU 486, of high affinity for RG. Moreover, plasma membrane seems affected by steroid hormones since cell adhesiveness is increased in the presence of androgens or estrogens but decreased in the presence of glucocorticosteroids, effects which are also abolished by the corresponding anti-hormones. These observations were made using culture medium supplemented with charcoal extracted calf serum, and were confirmed in serum free culture medium (SF). The doubling time in SF medium is longer, 24 h instead of 18 h. However, after long term cultures in SF medium (4 months) no change in receptor concentrations was observed and the 18 h doubling time was immediately restored in serum containing culture medium.


Progesterone Receptor Sedimentation Coefficient Receptor Concentration Synthetic Estrogen Serum Free 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baulieu EE, Atger M, Best-Belpomme M, Corvol P, Courvalin JC, Mester J, Milgrom E, Robel P, Rochefort H, DeCatalogne D (1975) Vit Horm 33: 649–731CrossRefGoogle Scholar
  2. Evans VJ, Bryant JC, Fioramonti MC, McQuilkin WT, Sanford KK, Earle WR (1956) Cancer Res 16: 77–86PubMedGoogle Scholar
  3. Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE (1982) CR Acad Sci Paris 294: 933–938Google Scholar
  4. Jensen EV, DeSombre ER (1972) Ann Rev Biochem 41: 203PubMedCrossRefGoogle Scholar
  5. Jung-Testas I, Bayard F, Baulieu EE (1976) Nature 259: 136–138PubMedCrossRefGoogle Scholar
  6. Jung-Testas I, Baulieu EE (1979) Exp Cell Res 119: 75–85PubMedCrossRefGoogle Scholar
  7. Philibert D, Deraedt R, Teutsch G (1981) 8th Congress on Pharmacology, Tokyo, abstract.Google Scholar
  8. Pratt WB, Aronow L (1966) J Biol Chem 241: 5244–5250PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • I. Jung-Testas
    • 1
  • E. E. Baulieu
    • 1
  1. 1.INSERM U 33, Laboratoire de HormonesUniversité Paris XIBicêtreFrance

Personalised recommendations